Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Edmundo Muniz, Michael Tomasic, and Charles Cantor


Certara has hired Edmundo Muniz as its CEO.

Muniz joins Certara from Kirax Corporation, where he had served as president and CEO since 2005 focusing on acquiring, developing, and commercializing specialty care therapies for oncology, pain, inflammation, acute, and supportive care. Prior to that, he held several senior executive roles at Eli Lilly.

BioData has appointed Michael Tomasic to its board of directors.

Tomasic served as President and CEO of CambridgeSoft for 20 years, which was acquired by PerkinElmer for over $200 million. He also served as Chairman of LabTech Corporation.

InSilio Medicine said this week that Charles Cantor will chair its scientific advisory board.

Cantor is the co-founder of Sequenom, a company engaged in non-invasive prenatal diagnostics; and Retrotope, a company that is developing isotopically-fortified organic compounds to bolster stress resistance and combat age-related diseases. He also acts as a consultant for several companies within the biotechnology industry.

In addition, Cantor is professor emeritus at the Boston University, a distinguished adjunct professor at the University of California, Irvine, and adjunct professor at the Moscow Institute of Physics and Technology and at Scripps Research Institute. He was also involved in the Human Genome Project. Cantor earned his bachelor's degree in chemistry at Columbia College, and got his doctorate from the University of California, Berkeley.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.